Two numbers, and everything hiding behind them
Ask what CAR-T costs and you will get one of two answers. In the United States, the drug alone lists at $373,000 to $475,000. In China, the same class of product lists at ¥899,000 to ¥1,299,000 — roughly $135,000 to $195,000 at ¥6.67 to the dollar.
That looks like a 60% saving, and it is real. But the drug price is the most visible number in a cost chain that has at least eight links, and the gap between "list price" and "what the family actually pays" is where most patients get surprised.
This is a line-by-line comparison of what CAR-T costs in the two countries in 2026 — the drug, the hospital stay, the ICU contingency, the payment systems on each side, and the costs that never appear in a price list.

The full cost chain, in plain terms
CAR-T is not an infusion you receive and pay for once. It is a sequence, and each stage bills separately:
- Workup — imaging, organ function, cardiac clearance, infectious disease screening, biomarker testing
- Leukapheresis — collecting your T cells, one session, plus the lab handling
- Manufacturing — the engineered cell product itself (this is the headline "drug price")
- Bridging therapy — optional low-dose chemotherapy to hold the disease steady while cells are made
- Lymphodepletion — conditioning chemotherapy in the days before infusion
- Inpatient monitoring — a dedicated ward, typically one to three weeks
- ICU contingency — needed in a minority of patients, and ruinous when unplanned
- Follow-up — Day 30, Day 90, imaging, blood counts, possible readmission
The drug price covers stage 3 only. Everything else is charged on top, in both countries — the difference is how much.
Side by side
| Cost element | United States | China |
|---|---|---|
| CAR-T product (list) | $373,000–$475,000 | $135,000–$195,000 (¥899K–¥1.299M) |
| Leukapheresis | Usually bundled into the hospital claim | ¥10,000–¥30,000 |
| Lymphodepletion chemotherapy | Bundled or billed separately | ¥5,000–¥20,000 |
| Inpatient stay (1–3 weeks) | $100,000–$300,000 for the admission | ¥30,000–¥120,000 |
| ICU contingency | Frequently six figures if used | ¥20,000–¥80,000 |
| Workup and imaging | $20,000–$60,000 | ¥5,000–¥20,000 |
| Follow-up through Day 90 | $10,000–$40,000 | ¥5,000–¥25,000 |
| Realistic all-in total | $499,000 – $1,000,000+ | $157,000 – $255,000 |
The Chinese ranges vary by product: a ¥899,000 product (rani-cel) lands nearer $157,000–$195,000 all-in, while a ¥1,299,000 product (relma-cel) lands nearer $217,000–$255,000.
One benchmark worth knowing: US hospitals are paid roughly $314,000 per CAR-T admission under Medicare's MS-DRG 018 in fiscal 2026, up 16.8% year on year — a figure that reflects the real resource intensity of the admission, not the drug markup.
What US insurance actually covers — and what it does not
This is the part international patients most often misunderstand about the American price, and the part American patients most often discover too late.
Medicare covers CAR-T. The drug is generally covered, and the admission is paid under MS-DRG 018. What Medicare does not do is pay all of it: Part B coinsurance is 20% of the Medicare-approved amount. On a $400,000 therapy, that is an $80,000 patient liability before any supplemental plan, and most Medigap plans do not fully absorb it.
Commercial insurance covers it too — with conditions. Prior authorisation, in-network centres, and often a requirement that you have failed specific prior lines of therapy. Approval is not automatic and can take weeks.
Manufacturer copay assistance exists — but usually excludes Medicare. Patient-assistance programmes can reduce commercial copay dramatically. Government-insured patients are generally excluded from these programmes by law, which is exactly the group with the largest 20% exposure.
Total cost of care runs above the drug price. Published US analyses place all-in CAR-T care at $499,000 to over $1 million per patient. The upper end is usually an ICU stay.
What Chinese payment actually covers — and who qualifies
In China, the published price is a cash price, not an insurance-negotiated number, and that single fact changes the maths in both directions.
Chinese domestic patients have real help. Five CAR-T products entered China's commercial innovative-drug insurance list effective 1 January 2026, and city-level supplemental schemes (惠民保) reimburse a share of the cost. Reported out-of-pocket figures for enrolled domestic patients range from roughly ¥40,000 to ¥200,000 — a life-changing difference. But the schemes have deductibles, caps and enrolment windows, and a patient who buys in after diagnosis usually cannot claim.
International self-pay patients do not qualify for any of it. No Chinese public insurance, no city supplemental scheme, no manufacturer assistance programme for foreign patients. The list price is the price, paid to the hospital, with a formal invoice (发票).
The Chinese price is still the lower cash price in the world for this class of therapy. A US patient paying cash faces $499,000 and up. The same patient paying cash in China faces $157,000–$255,000 — which is why The Wall Street Journal reported in 2026 that American patients are beginning to travel to China for CAR-T.
Three scenarios, priced honestly
Costs only become comparable once you fix the disease.
| Scenario | United States (cash or high coinsurance) | China (self-pay) |
|---|---|---|
| DLBCL, second line, standard CD19 product, no ICU | ~$520,000–$650,000 | ~$160,000–$185,000 |
| Multiple myeloma, third line, BCMA product, 2 weeks inpatient | ~$500,000–$600,000 | ~$185,000–$215,000 |
| Gastric cancer, third line, satri-cel (China only) | Not available at any price | ~$170,000–$200,000 |
The third row is the one that reframes the whole comparison. For CLDN18.2-positive gastric cancer, there is no US price to compare against, because no regulator outside China has approved a CAR-T for a solid tumour. "Cheaper" is not the relevant category; "available" is.
The five costs nobody puts in the quote
Every one of these has caught out a real family.
Travel and accommodation. Two to three months in a Chinese city, with a companion, runs $5,000–$15,000 depending on city and standard. Shanghai and Beijing cost more than Tianjin or Hangzhou.
Repeat infusions. satri-cel's label allows up to three infusions. Each re-infusion requires a fresh lymphodepletion course and another inpatient stay. A quote for one infusion is not a quote for the course.
Bridging therapy. If your disease is progressing while cells are manufactured, you may need chemotherapy in between — extra weeks, extra cost, extra risk.
Complications. Fever, cytopenias, infection and ICU care are not hypothetical. Ask explicitly what the ICU day rate is and whether it is included in any package price.
Follow-up after you fly home. Your home oncologist will need to manage cytopenias, immunoglobulin replacement and imaging. Some will; some will not accept responsibility for a therapy they did not deliver. Settle this before you travel, not after.
When the money is actually requested — and the three questions to get answered in writing before you pay — is set out in the payment timeline in our patient journey guide.

What the lower price does not buy
A cheaper bill is not the whole story, and pretending otherwise would be dishonest.
You are buying a different health system's continuity. In the US, your CAR-T team, your oncologist and your insurer are in one system. In China, you are a self-pay international patient at a hospital that may never see you again after Day 90.
You are accepting travel risk. Cytopenias and infection risk persist for months. Flying long-haul at Day 30 with a neutrophil count near zero is a genuine hazard, and it is the reason most programmes insist on monitoring near the hospital before discharge.
You are giving up legal recourse you understand. Malpractice frameworks, complaint routes and insurance arbitration differ. This matters less than clinical outcomes and more than most patients expect.
You are paying cash up front. Chinese hospitals generally require payment before or during treatment, not after insurance adjudication. Few offer payment plans to foreign patients.
One structural difference worth knowing: some options are a course, others are a subscription. In myeloma a BCMA bispecific is paid per dose indefinitely, while CAR-T is a single purchase — we priced the two side by side.

How to compare two quotes properly
If you are holding a US estimate and a Chinese estimate, they are probably not measuring the same thing. Ask both sides for the same ten lines, in writing:
- Product name, target and dose, with list price
- Leukapheresis and cell handling
- Manufacturing timeline and what happens if manufacturing fails
- Bridging therapy, if needed
- Lymphodepletion regimen and drugs
- Ward type and daily rate; expected number of days
- ICU day rate and how often it is used
- Workup, imaging and biomarker testing
- Follow-up visits through Day 90, itemised
- What is explicitly not included
The last line is the one that separates a real quote from a brochure.
The honest caveats
CAR-T is expensive everywhere because it is genuinely expensive to make. One batch, one patient, weeks of GMP manufacturing. China's lower price reflects lower manufacturing and hospital costs, not a cheaper molecule — and it is still out of reach for most Chinese patients, with published estimates suggesting only 5–10% of eligible patients can access it.
Cost-effectiveness is contested even at the Chinese price. Peer-reviewed analyses of CAR-T in DLBCL have found it is not cost-effective at conventional willingness-to-pay thresholds, in either country. That is an argument about health economics, not about whether an individual patient should be treated.
Prices move. Chinese CAR-T pricing has been falling as competition grows — ten approved products as of November 2026 — and reimbursement negotiations are ongoing. A quote from last year is not a quote today.
The cheapest option is not always the right one. A centre with a dedicated CAR-T ward, ICU backup and experience managing grade 3 cytokine release syndrome is worth more than a $20,000 discount.
If the patient is a child, read our guide to CAR-T for children with relapsed B-ALL in China first — the paediatric indication, the trial data and the bridge to transplant work differently from the adult pathway.
Getting started
The practical first step is not a price list — it is a written, itemised estimate against your actual diagnosis, because the product, the number of infusions and the ICU risk all change with the disease and the line of therapy.
MedChinaGo's CAR-T programme reviews pathology and prior treatment records, matches the case to an approved product or a trial, and returns an itemised estimate covering product, apheresis, conditioning, ward, ICU contingency and follow-up — before any payment is made. Learn more about CAR-T therapy in China, see which products are approved in China, or read the comparison of CAR-T, transplant and chemotherapy if the treatment decision itself is still open.

